MEDICINAL COMPOSITIONS OF CANNABINOIDS AND XANTHINES
Various embodiments relate to bioactive compositions, including a first component including 1 to 300 mg/dose of a psychotropic cannabinoid, a non-psychotropic cannabinoid, or a mixture thereof; a second component including 1 to 400 mg/dose of a methylxanthine; and an aqueous carrier.
1 . A nutraceutical composition, comprising:
an aqueous carrier; and
a powder suspended in the aqueous carrier,
wherein the powder comprises a mixture of:
a first component comprising 1 to 300 mg/dose of a psychotropic cannabinoid, a non-psychotropic cannabinoid, or a mixture thereof;
a second component comprising 1 to 400 mg/dose of a methylxanthine.
2 . The nutraceutical composition of claim 1 , wherein said first component is selected from the group consisting of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), cannabigerol (CBG), Cannabinol (CBN), cannabichromene (CBC), cannabidivarin (CBDV), and mixtures thereof.
3 . The nutraceutical composition of claim 1 , wherein said methylxanthine is selected from the group consisting of caffeine, aminophylline, dyphylline, 3-isobutyl-1methylxanthine, paraxanthine, pentoxifylline, theobromine, theophylline, and mixtures thereof.
4 . The nutraceutical composition of claim 1 , wherein said methylxanthine is selected from the group consisting of caffeine, aminophylline, dyphylline, 3-isobutyl-1methylxanthine, paraxanthine, pentoxifylline, and mixtures thereof.
5 . The nutraceutical composition of claim 1 , further comprising an extract of valerian containing a valerenic acid selected from the group consisting of valerenic acid, hydroxyvalerenic acid, acetoxyvalerenic acid, and mixtures thereof.
6 . The nutraceutical composition of claim 1 , wherein said composition is in the form of an orally administrable liquid composition.
7 . The nutraceutical composition of claim 6 , wherein said orally administrable liquid composition comprises water, fruit juice, yogurt, or pudding.
8 . The nutraceutical composition of claim 6 , wherein said composition is in the form of a dispersion or suspension of a powder in an aqueous medium.
9 . A nutraceutical composition, comprising:
a first component comprising 2 to 50 mg/dose of a psychotropic cannabinoid, a non-psychotropic cannabinoid, or a mixture thereof;
a second component comprising 80 to 300 mg/dose of a methylxanthine; and
an aqueous carrier,
wherein the nutraceutical composition is free of non-cannabinoid active components of Cannabis sattiva and the nutraceutical composition contains no active components of coffee other than the methylxanthine.
10 . The nutraceutical composition of claim 9 , wherein the first component and the second component are used in a ratio from 1:5 to 1:12.
11 . A method comprising:
administering an effective amount of a nutraceutical composition to a mammal in need thereof,
wherein the nutraceutical composition comprises:
a first component comprising 1 to 300 mg/dose of a psychotropic cannabinoid, a non-psychotropic cannabinoid, or a mixture thereof; and
a second component comprising 1 to 400 mg/dose of a methylxanthine; and
imparting a nootropic effect beyond effects obtained by the first component alone.
12 . A method comprising:
administering an effective amount of a nutraceutical composition to a mammal in need thereof, wherein the nutraceutical composition comprises
a first component comprising 10 to 50 mg/dose of a psychotropic cannabinoid, a non-psychotropic cannabinoid, or a mixture thereof; and
a second component comprising 80 to 300 mg/dose of a methylxanthine; and
imparting a nootropic effect beyond effects obtained by the first component alone.
13 . The method of claim 11 , wherein said administering is once a day over a period of treatment of one—eight weeks.
14 . The method of claim 12 , wherein said administering is once a day over a period of treatment of one—eight weeks.
15 . The method of claim 11 , wherein the method includes, prior to said administering,
providing said nutraceutical composition in a powder form;
dispersing or suspending the nutraceutical composition in an aqueous vehicle or carrier to form a liquid composition.
16 . The method of claim 12 , wherein the method includes, prior to said administering,
providing said nutraceutical composition in a powder form;
dispersing or suspending the nutraceutical composition in an aqueous vehicle or carrier to form a liquid composition.
17 . The nutraceutical composition of claim 1 , wherein the composition is in the form of a powder.
18 . The nutraceutical composition of claim 9 , wherein the composition is in the form of a powder.
19 . The nutraceutical composition of claim 9 , further comprising an extract of valerian or arugula.